SwePub - search: WFRF:(Rogers C)

Enumeration	Reference	Cover	Find
1.	2021 swepub:Mat__t
2.	Kanai, M, et al. (author) 2023 swepub:Mat__t
3.	Niemi, MEK, et al. (author) 2021 swepub:Mat__t
4.	2017 swepub:Mat__t
5.	Tabiri, S, et al. (author) 2021 swepub:Mat__t
6.	Bravo, L, et al. (author) 2021 swepub:Mat__t
7.	Glasbey, JC, et al. (author) 2021 swepub:Mat__t
8.	2021 swepub:Mat__t
9.	Adamina, M, et al. (author) The impact of surgical delay on resectability of colorectal cancer: An international prospective cohort study 2022 In: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. - : Wiley. - 1463-1318. ; 24:6, s. 708-726 Journal article (peer-reviewed)
10.	Bonaca, MP, et al. (author) Long-term use of ticagrelor in patients with prior myocardial infarction 2015 In: The New England journal of medicine. - 1533-4406. ; 372:19, s. 1791-1800 Journal article (peer-reviewed)
11.	Jakobsson, J., et al. (author) Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 2021 In: Autophagy. - : Informa UK Limited. - 1554-8635 .- 1554-8627. ; 17:1, s. 1-382 Journal article (peer-reviewed)
12.	Khatri, C, et al. (author) Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study 2021 In: BMJ open. - : BMJ. - 2044-6055. ; 11:11, s. e050830- Journal article (peer-reviewed)abstract Studies have demonstrated high rates of mortality in people with proximal femoral fracture and SARS-CoV-2, but there is limited published data on the factors that influence mortality for clinicians to make informed treatment decisions. This study aims to report the 30-day mortality associated with perioperative infection of patients undergoing surgery for proximal femoral fractures and to examine the factors that influence mortality in a multivariate analysis.SettingProspective, international, multicentre, observational cohort study.ParticipantsPatients undergoing any operation for a proximal femoral fracture from 1 February to 30 April 2020 and with perioperative SARS-CoV-2 infection (either 7 days prior or 30-day postoperative).Primary outcome30-day mortality. Multivariate modelling was performed to identify factors associated with 30-day mortality.ResultsThis study reports included 1063 patients from 174 hospitals in 19 countries. Overall 30-day mortality was 29.4% (313/1063). In an adjusted model, 30-day mortality was associated with male gender (OR 2.29, 95% CI 1.68 to 3.13, p<0.001), age >80 years (OR 1.60, 95% CI 1.1 to 2.31, p=0.013), preoperative diagnosis of dementia (OR 1.57, 95% CI 1.15 to 2.16, p=0.005), kidney disease (OR 1.73, 95% CI 1.18 to 2.55, p=0.005) and congestive heart failure (OR 1.62, 95% CI 1.06 to 2.48, p=0.025). Mortality at 30 days was lower in patients with a preoperative diagnosis of SARS-CoV-2 (OR 0.6, 95% CI 0.6 (0.42 to 0.85), p=0.004). There was no difference in mortality in patients with an increase to delay in surgery (p=0.220) or type of anaesthetic given (p=0.787).ConclusionsPatients undergoing surgery for a proximal femoral fracture with a perioperative infection of SARS-CoV-2 have a high rate of mortality. This study would support the need for providing these patients with individualised medical and anaesthetic care, including medical optimisation before theatre. Careful preoperative counselling is needed for those with a proximal femoral fracture and SARS-CoV-2, especially those in the highest risk groups.Trial registration numberNCT04323644
13.	Corbalan, R, et al. (author) Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry 2019 In: JAMA cardiology. - : American Medical Association (AMA). - 2380-6591 .- 2380-6583. ; 4:6, s. 526-548 Journal article (peer-reviewed)
14.	Glasbey, JC, et al. (author) Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study 2021 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - : American Society of Clinical Oncology. - 1527-7755 .- 0732-183X. ; 39:1, s. 66- Journal article (peer-reviewed)
15.	Braisch, U, et al. (author) Identification of symbol digit modality test score extremes in Huntington's disease 2019 In: American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. - : Wiley. - 1552-485X .- 1552-4841. ; 180:3, s. 232-245 Journal article (peer-reviewed)
16.	Aaltonen, T., et al. (author) Combination of Tevatron Searches for the Standard Model Higgs Boson in the W+W- Decay Mode 2010 In: Physical Review Letters. - 0031-9007 .- 1079-7114. ; 104:6, s. 061802- Journal article (peer-reviewed)abstract We combine searches by the CDF and D0 Collaborations for a Higgs boson decaying to W+W-. The data correspond to an integrated total luminosity of 4.8 (CDF) and 5.4 (D0) fb(-1) of p (p) over bar collisions at root s = 1.96 TeV at the Fermilab Tevatron collider. No excess is observed above background expectation, and resulting limits on Higgs boson production exclude a standard model Higgs boson in the mass range 162-166 GeV at the 95% C.L.
17.	Jukema, JW, et al. (author) Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1167-1176 Journal article (peer-reviewed)
18.	Ray, KK, et al. (author) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 2019 In: The lancet. Diabetes & endocrinology. - 2213-8595 .- 2213-8587. ; 7:8, s. 618-628 Journal article (peer-reviewed)
19.	Roe, MT, et al. (author) Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 2019 In: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 1524-4539 .- 0009-7322. ; 140:19, s. 1578-1589 Journal article (peer-reviewed)
20.	Szarek, M, et al. (author) Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial 2019 In: Circulation. Cardiovascular quality and outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 12:11, s. e005858- Journal article (peer-reviewed)
21.	Szarek, M, et al. (author) Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 73:4, s. 387-396 Journal article (peer-reviewed)
22.	Andiman, W, et al. (author) The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies 1999 In: The New England journal of medicine. - 0028-4793. ; 340:13, s. 977-987 Journal article (peer-reviewed)
23.	Fox, Z, et al. (author) Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2 2007 In: HIV medicine. - : Wiley. - 1464-2662 .- 1468-1293. ; 8:2, s. 112-123 Journal article (peer-reviewed)
24.	Aaltonen, T., et al. (author) Evidence for a Particle Produced in Association with Weak Bosons and Decaying to a Bottom-Antibottom Quark Pair in Higgs Boson Searches at the Tevatron 2012 In: Physical Review Letters. - 0031-9007 .- 1079-7114. ; 109:7, s. 071804- Journal article (peer-reviewed)abstract We combine searches by the CDF and D0 Collaborations for the associated production of a Higgs boson with a W or Z boson and subsequent decay of the Higgs boson to a bottom-antibottom quark pair. The data, originating from Fermilab Tevatron p (p) over bar collisions at root s = 1.96 TeV, correspond to integrated luminosities of up to 9.7 fb(-1). The searches are conducted for a Higgs boson with mass in the range 100-150 GeV/c(2). We observe an excess of events in the data compared with the background predictions, which is most significant in the mass range between 120 and 135 GeV/c(2). The largest local significance is 3.3 standard deviations, corresponding to a global significance of 3.1 standard deviations. We interpret this as evidence for the presence of a new particle consistent with the standard model Higgs boson, which is produced in association with a weak vector boson and decays to a bottom-antibottom quark pair.
25.	Bittner, VA, et al. (author) Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome 2020 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 75:2, s. 133-144 Journal article (peer-reviewed)

Skapa referenser, mejla, bekava och länka

Permalink

Träfflista för sökning "WFRF:(Rogers C) "

Refine your search

Year